158 related articles for article (PubMed ID: 28337663)
1. Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).
Kawaguchi H; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Saji S; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita T; Yamamoto Y; Ohno S; Toi M
Breast Cancer Res Treat; 2017 Jun; 163(3):545-554. PubMed ID: 28337663
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.
Kawaguchi H; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Saji S; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita H; Yamashita T; Yamamoto Y; Yotsumoto D; Toi M; Ohno S
Curr Med Res Opin; 2018 Jan; 34(1):49-54. PubMed ID: 29095648
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
Masuyama M; Masuda N; Kawaguchi H; Yamamoto Y; Saji S; Nakayama T; Aogi K; Anan K; Ohtani S; Sato N; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita T; Yotsumoto D; Toi M; Ohno S
Cancer Med; 2023 Sep; 12(17):17718-17730. PubMed ID: 37525895
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
Kawaguchi H; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Saji S; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita H; Yamashita T; Yamamoto Y; Yotsumoto D; Toi M; Ohno S
Breast Cancer; 2020 May; 27(3):389-398. PubMed ID: 31811519
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure.
Araki K; Ishida N; Horii R; Takahashi S; Akiyama F; Ito Y; Ohno S
Expert Opin Pharmacother; 2015; 16(17):2561-8. PubMed ID: 26558799
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
[TBL] [Abstract][Full Text] [Related]
7. First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.
Di Leo A; Jerusalem G; Torres R; Verhoeven D; Pendergrass K; Malorni L; Lichfield J; Martin M
Breast; 2018 Apr; 38():144-149. PubMed ID: 29324303
[TBL] [Abstract][Full Text] [Related]
8. Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience.
Ishida N; Araki K; Sakai T; Kobayashi K; Kobayashi T; Fukada I; Hosoda M; Yamamoto M; Ichinokawa K; Takahashi S; Iwase T; Ito Y; Yamashita H
Breast Cancer; 2016 Jul; 23(4):617-23. PubMed ID: 25896598
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
10. Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study).
Kimizuka K; Inoue K; E Nagai S; Saito T; Nakano S; Futsuhara K; Yamada H; Kaneko S; Sakurai T; Hata S; Kurosumi M
J Nippon Med Sch; 2019; 86(3):165-171. PubMed ID: 31292328
[TBL] [Abstract][Full Text] [Related]
11. Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients.
Warm M; Kates R; Overkamp F; Thomas A; Harbeck N
Breast Cancer Res Treat; 2011 Jan; 125(1):127-36. PubMed ID: 20960229
[TBL] [Abstract][Full Text] [Related]
12. [Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer].
Martínez Marín V; Muñoz Martín AJ; Viñuela Benéitez MC; García Alfonso P; Alonso Muñoz A; Pérez Manga G
Med Clin (Barc); 2009 Sep; 133(10):371-4. PubMed ID: 19339025
[TBL] [Abstract][Full Text] [Related]
13. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Xu B; Jiang Z; Shao Z; Wang J; Feng J; Song S; Chen Z; Gu K; Yu S; Zhang Y; Wang C; Zhang F; Yang J
Cancer Chemother Pharmacol; 2011 Jan; 67(1):223-30. PubMed ID: 20938664
[TBL] [Abstract][Full Text] [Related]
14. [Experience of Fulvestrant for Hormone Receptor-Positive HER2-Negative Advanced and Metastatic Breast Cancer].
Soshi M; Kawasaki S; Kawamura Y; Watanebe A; Iguchi E; Nishida M; Sakuramachi A; Morita M; Oouchi Y; Nakatsukasa K; Sakaguchi K; Taguchi T
Gan To Kagaku Ryoho; 2018 Jun; 45(6):949-954. PubMed ID: 30026420
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Kawaguchi H; Yamamoto Y; Saji S; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita H; Yamashita T; Yotsumoto D; Toi M; Ohno S
Jpn J Clin Oncol; 2022 May; 52(6):545-553. PubMed ID: 35296894
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F
Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095
[TBL] [Abstract][Full Text] [Related]
18. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models.
Cope S; Ouwens MJ; Jansen JP; Schmid P
Value Health; 2013; 16(2):403-17. PubMed ID: 23538193
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.
Martín M; Loibl S; von Minckwitz G; Morales S; Martinez N; Guerrero A; Anton A; Aktas B; Schoenegg W; Muñoz M; Garcia-Saenz JÁ; Gil M; Ramos M; Margeli M; Carrasco E; Liedtke C; Wachsmann G; Mehta K; De la Haba-Rodriguez JR
J Clin Oncol; 2015 Mar; 33(9):1045-52. PubMed ID: 25691671
[TBL] [Abstract][Full Text] [Related]
20. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]